ECM
ABVX

ExodusPoint Capital Management’s Abivax ABVX Stock Holding History

ExodusPoint Capital Management’s Portfolio ABVX Stock Details ABVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$49.4M Buy
371,000
+318,300
+604% +$36M 0.32% 45
2026
Q1 		$5.87M Buy
52,700
+16,500
+46% +$1.95M 0.05% 392
2025
Q4 		$4.88M Buy
+36,200
New +$3.95M 0.04% 478

Other funds holding ABVX

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
HI
Helikon Investments London, United Kingdom $3.35B AUM 55.08% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

ExodusPoint Capital Management's ABVX Position: Q2 2026 in Review

ExodusPoint Capital Management reduced its Abivax (ABVX) stake by 78% in Q2 2026, selling an estimated $12.3M and leaving 31,209 shares worth $4.16M. The position accounts for 0.03% of the portfolio, ranked #557.

ExodusPoint Capital Management first reported a position in ABVX in Q4 2025 and has held it in 3 quarters since. The position peaked at $29M in Q4 2025. 303 funds tracked by Wall St. Rank hold ABVX as of Q2 2026.

  • ExodusPoint Capital Management held 31,209 shares of Abivax worth $4.16M as of Q2 2026.
  • ExodusPoint Capital Management sold 109,053 Abivax shares in Q2 2026, an estimated $12.3M.
  • Abivax made up 0.03% of ExodusPoint Capital Management's portfolio in Q2 2026, its #557 holding.
  • ExodusPoint Capital Management first reported a position in Abivax in Q4 2025 and has held it in 3 quarters since.
  • ExodusPoint Capital Management's Abivax position peaked at $29M in Q4 2025.
  • 303 funds tracked by Wall St. Rank held Abivax as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.